Associations between inflammation, nocturnal back pain and fatigue in ankylosing spondylitis and improvements with etanercept therapy
Authors:
Open Access
- 26 June 2013
- journal article
- research article
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 41 (4) , 1150-1159
Abstract
Objectives To investigate the relationships between inflammation, nocturnal back pain and fatigue in ankylosing spondylitis (AS) and the impact of 12 weeks' etanercept treatment versus sulfasalazine or placebo. Methods Data were combined from four clinical trials for patients with AS who received at least one dose of etanercept, sulfasalazine or placebo and had at least one postbaseline assessment value. Linear regression was performed (controlling for site, protocol and demographics), to explore the relationship between inflammation (C-reactive protein [CRP]), nocturnal back pain (visual analog scale [VAS] 0–100 mm) and fatigue (VAS 0–100 mm Bath AS Disease Activity Index fatigue item). Results Out of 1283 patients (etanercept, n = 867; sulfasalazine, n = 187; placebo, n = 229), improvement in nocturnal back pain was a significant predictor of improvement in fatigue. Significant correlations were found between nocturnal back pain and fatigue, but not CRP levels. Etanercept provided significantly greater pain/fatigue improvement than sulfasalazine or placebo. Improvements in nocturnal back pain and fatigue had weak relationships with improvement in inflammation (CRP level). Conclusions AS patients treated with etanercept demonstrated superior improvement in nocturnal back pain and fatigue versus sulfasalazine or placebo. Decrease in nocturnal back pain can improve fatigue. Assessing treatment response using CRP levels alone may be misleading without also examining patient-reported outcomes such as back pain and fatigue.Keywords
This publication has 25 references indexed in Scilit:
- Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort studyArthritis Research & Therapy, 2011
- Predicting the outcome of ankylosing spondylitis therapyAnnals of the Rheumatic Diseases, 2011
- Fatigue in patients with ankylosing spondylitis: prevalence and relationships with disease-specific variables, psychological status, and sleep disturbanceRheumatology International, 2011
- Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registryAnnals of the Rheumatic Diseases, 2010
- Quality of life and related variables in patients with ankylosing spondylitisQuality of Life Research, 2010
- Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics RegisterRheumatology, 2009
- ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitisAnnals of the Rheumatic Diseases, 2009
- Fatigue in patients with ankylosing spondylitis: A comparison with the general population and associations with clinical and self‐reported measuresArthritis Care & Research, 2005
- Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor α blockers in ankylosing spondylitisAnnals of the Rheumatic Diseases, 2004
- Sleep disturbances in outpatients with ankylosing spondylitis - a questionnaire study with gender implicationsScandinavian Journal of Rheumatology, 2000